357 related articles for article (PubMed ID: 2974448)
1. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
[TBL] [Abstract][Full Text] [Related]
2. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate.
Arkin H; Ohnuma T; Kamen BA; Holland JF; Vallabhajosula S
Cancer Res; 1989 Dec; 49(23):6556-61. PubMed ID: 2573416
[TBL] [Abstract][Full Text] [Related]
4. Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by perhexiline maleate.
Ramu A; Fuks Z; Gatt S; Glaubiger D
Cancer Res; 1984 Jan; 44(1):144-8. PubMed ID: 6690032
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Hait WN; Pierson NR
Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
[TBL] [Abstract][Full Text] [Related]
6. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
7. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate.
Diddens H; Niethammer D; Jackson RC
Cancer Res; 1983 Nov; 43(11):5286-92. PubMed ID: 6225514
[TBL] [Abstract][Full Text] [Related]
8. N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.
Takemura Y; Ohnuma T
Mt Sinai J Med; 1992 Oct; 59(5):419-24. PubMed ID: 1435841
[TBL] [Abstract][Full Text] [Related]
9. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
Lepri E; Menconi E; Barzi AM
Boll Soc Ital Biol Sper; 1984 Jul; 60(7):1369-75. PubMed ID: 6477749
[TBL] [Abstract][Full Text] [Related]
10. Ornithine decarboxylase--a predictor for tumor chemosensitivity.
Bachrach U; Shayovitz A; Marom Y; Ramu A; Ramu N
Cell Mol Biol (Noisy-le-grand); 1994 Nov; 40(7):957-64. PubMed ID: 7849562
[TBL] [Abstract][Full Text] [Related]
11. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.
Inaba M; Kobayashi H; Sakurai Y; Johnson RK
Cancer Res; 1979 Jun; 39(6 Pt 1):2200-3. PubMed ID: 445418
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of sensitivity to adriamycin in resistant P388 leukemia by the calmodulin inhibitor trifluoperazine.
Ganapathi R; Grabowski D
Cancer Res; 1983 Aug; 43(8):3696-9. PubMed ID: 6861140
[TBL] [Abstract][Full Text] [Related]
13. Plasma membrane lipid structural order in doxorubicin-sensitive and -resistant P388 cells.
Ramu A; Glaubiger D; Magrath IT; Joshi A
Cancer Res; 1983 Nov; 43(11):5533-7. PubMed ID: 6311408
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of doxorubicin and vinblastine sensitivity in anthracycline-resistant P388 cells.
Ramu A; Shan TC; Glaubiger D
Cancer Treat Rep; 1983 Oct; 67(10):895-9. PubMed ID: 6354437
[TBL] [Abstract][Full Text] [Related]
15. Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells.
Ramu A; Glaubiger D; Weintraub H
Cancer Treat Rep; 1984 Apr; 68(4):637-41. PubMed ID: 6713419
[TBL] [Abstract][Full Text] [Related]
16. Exploring multidrug resistance using rhodamine 123.
Kessel D
Cancer Commun; 1989; 1(3):145-9. PubMed ID: 2639727
[TBL] [Abstract][Full Text] [Related]
17. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
Johnson RK; Chitnis MP; Embrey WM; Gregory EB
Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
[TBL] [Abstract][Full Text] [Related]
18. Differential effect of collaterally sensitive antimetabolites on P388 murine leukemia sensitive and resistant to adriamycin in vitro.
Satyamoorthy K; Deshpande SS; Chitnis MP
Neoplasma; 1989; 36(6):673-83. PubMed ID: 2515459
[TBL] [Abstract][Full Text] [Related]
19. Characterization of four drug-resistant P388 sublines: resistance/sensitivity in vivo, resistance-and proliferation-markers, immunogenicity.
Fichtner I; Stein U; Hoffmann J; Winterfeld G; Pfeil D; Hentschel M
Anticancer Res; 1994; 14(5A):1995-2003. PubMed ID: 7847840
[TBL] [Abstract][Full Text] [Related]
20. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]